A cross between a nicotine pouch and an energy drink: What to know about caffeine pouches
They'll use them either as a disguise for nicotine pouch usage — caffeine and nicotine pouches often look virtually identical — or a complement to it, Gomez said.
'They'll use the Zyn pouches that they put in their lip, and then they'll take a caffeine pouch,' he added. 'They don't care what it is they're putting in their lip.'
The use of caffeine pouches among teens is still relatively rare. But some experts and educators have concerns that that could soon change. Teen-friendly marketing of these products is spreading on social media. And Richard Mumby, the marketing executive who helped launch the e-cigarette Juul, which was widely blamed for sparking a teen vaping epidemic, is back with a caffeine pouch startup called Wip.
Wip joins a growing market drafting off the popularity of nicotine pouches and trying to sell Americans on a new alternative to caffeinated beverages.
Caffeine is part of 'the fabric of many Americans' everyday lives,' Mumby told NBC News — but he argues there's room for improvement.
Wip and its competitors are pitching caffeine pouches as a convenient, portable and affordable alternative to caffeinated drinks. A cross between nicotine pouches and energy drinks, they are placed between the lip and gums to quickly deliver a hands-free hit of caffeine. Pouches typically last anywhere from roughly 20 minutes to an hour, but their caffeine buzz can linger longer.
Wip's pouches come in flavors like mint, strawberry kiwi and sour cherry, and each one contains either 100 or 200 milligrams of caffeine — the latter being roughly equivalent to two cups of coffee, or half the amount of caffeine most adults can safely consume in an entire day, according to the U.S. Food and Drug Administration.
The health effects of caffeine pouches are not well-studied. But not all experts are sold on this new form of caffeine delivery.
Rob van Dam, a professor of exercise and nutrition sciences at George Washington University's Milken Institute School of Public Health who studies caffeine, voiced concerns about the potency of some pouches on the market, particularly for consumers who are not used to them. 'It may be a bit different than coffee,' he said. 'It may hit faster, and you may overdose, in a way, more quickly.'
The potential appeal to teens is another concern, given the existing popularity of nicotine pouches and energy drinks. (Philip Morris, which makes Zyn, has previously told NBC News that 'Zyn's marketing is directed toward legal age nicotine users who are 21+.') While there are no federal age restrictions on the sale or use of caffeine, the American Academy of Pediatrics recommends that teens consume no more than 100 mg of caffeine per day — or, even better, avoid using it at all, said Dr. Mark Corkins, chair of the AAP's Committee on Nutrition.
Youth caffeine use came under increasing scrutiny following high-profile reports of death and serious injury among young people who consumed Panera Bread's heavily caffeinated Charged Lemonade, which the brand discontinued in 2024 as part of a 'menu transformation.' Separately, medical visits related to kids drinking other caffeinated beverages are also on the rise: From 2022 to 2023, America's Poison Centers charted a 24% increase in calls related to energy-drink consumption among people younger than 20. And the rate of pediatric emergency room visits related to caffeine usage roughly doubled between 2017 and 2023, although such visits remain rare, according to data from Epic Research.
'Caffeine, in general, is an area we are very concerned about,' Corkins said. 'Pouches are just another delivery form.'
A growing market — and an ethical 'gray zone'
Caffeine pouches aren't entirely new. The brand Grinds started selling coffee pouches about 15 years ago, initially targeting the niche market of baseball players who wanted an alternative to chewing tobacco. At first, business 'was like flying a plane into headwinds,' said co-founder Patrick Pezet. 'No one knew what pouches were. It was totally foreign.'
Business has increased steadily over time, growing by 20% to 50% each year since the company launched, Pezet said. Especially in the last five years or so — in parallel with the rise of the popular nicotine pouch brand Zyn — there's been a dramatic shift in the public's awareness of and willingness to use mouth pouches, Pezet said. (Wip said in a press release that almost half of adults ages 18 to 40 are interested in using pouches for energy.)
Caffeine pouches are still a small market, particularly compared to the multibillion-dollar U.S. coffee industry or even the nicotine pouch industry. Still, Pezet said, his company has a growing customer base, mostly made up of adults who want an alternative to nicotine products.
Another sign of growth: an explosion of competitors. 'We keep close tabs on the entire market,' Pezet said. 'There's probably 50 to 60 total caffeine pouches or energy pouches out there. Two or three years ago, that number was a couple dozen.'
As the market proliferates, it has given rise to a 'gray zone' of legal but ethically dubious promotion to young people, Pezet said. (A blog post on Grinds' website says 'there is absolutely no age restriction on purchasing or using Grinds Coffee Pouches,' but Pezet said the brand directs its marketing toward customers 18 and older.)
In some social media posts, creators explicitly promote caffeine pouches to students. 'Can you pop a lower decky in school?' asked an influencer in one TikTok post about pouches from the brand LyvWel, using a slang term for mouth pouches. 'One-hundred percent, guys. You can use the lower deckies in school. You don't have to be 21 to buy them.'
A representative for LyvWel said the post was not created, approved or sponsored by LyvWel. 'Although caffeine products are legally available to anyone who can purchase tea, coffee, or energy drinks, LyvWel was created specifically as an alternative for adult nicotine pouch users,' the representative wrote in an email. 'We do not market to teens.'
Some TikTok creators who review and promote caffeine pouches appear to be teenagers themselves, although it is not clear whether their posts have been approved by the brands they mention.
'Viral, organic social-media marketing'
Dr. Robert Jackler, a professor emeritus at Stanford Medicine who studies tobacco-industry advertising, sees echoes of Juul in Wip's marketing. Wip is active on TikTok and Instagram — two platforms used heavily by young people — and features athletes and fitness influencers in its posts, a combination that Jackler said is 'patently youth-oriented' and reminiscent of the lifestyle-focused, influencer-driven marketing campaigns that Juul ran under Mumby, now the Wip CEO.
Such marketing prompted multiple lawsuits alleging Juul purposely targeted underage customers. Juul executives have repeatedly denied that allegation and have not admitted wrongdoing in legal settlements. But the company's product became nearly synonymous with youth vaping at a time when almost 30% of high school students used e-cigarettes.
'[Mumby] is doing the same kind of viral, organic social-media marketing that he did with Juul,' Jackler said.
'We take responsible caffeine consumption and responsible marketing of our product seriously,' a Wip spokesperson said in a statement provided to NBC News. 'While there are no legal age restrictions on caffeine products, we have adopted marketing guidelines that exceed the age-related standards set by the American Beverage Association for most common energy drinks. Wip is not intended for use by anyone under the age of 18, and our guidelines ensure the product is marketed responsibly. We proactively train all external partners on our marketing guidelines so there is education and alignment at every layer of our business.'
Despite their spread online, caffeine pouches do not seem to be nearly as ubiquitous in schools as Juul was at its prime, nor as either energy drinks or nicotine pouches are today. An estimated 64% and 5% of teenagers have tried energy drinks and nicotine pouches, respectively, while there is little data on youth caffeine pouch usage.
Dylan Lippold, a middle school teacher in Wisconsin, said he remains more concerned about energy drink consumption among his students. 'I would walk into a class and see five or so kids drinking [an energy drink] in the morning,' he said. 'That's a little concerning that a middle schooler needs that much caffeine to get going for the day.'
Health concerns
Caffeine is often seen as a harmless, or even beneficial, stimulant — and within reason, it can be. Although most experts agree it's possible to become dependent on caffeine, it's not considered as addictive as nicotine. And in addition to providing energy and mental clarity, caffeine consumption can come with significant health benefits, studies conducted among adults have shown.
'In population studies, people drinking three or four cups of coffee per day have a lower risk of cardiovascular diseases, like coronary heart disease and stroke,' van Dam said. 'But going beyond that, like more than five cups of coffee per day, we do not see the same benefits.' And, he noted, it's not clear whether the caffeine in energy drinks or pouches carries the same benefits as classic coffee.
At high levels of consumption, caffeine can cause side effects that range from relatively benign (anxiety, jitters, GI distress, difficulty sleeping) to more worrisome (heart palpitations, high blood pressure, increased heart rate). In rare cases, heavy caffeine consumption can cause fatal complications, including cardiac arrest, studies show.
For children and teenagers, who are typically smaller and weigh less than adults, the thresholds of safe caffeine consumption are lower. The AAP recommends against pediatric caffeine usage not only because of the potential for toxicity, but also because kids who need to use a lot of caffeine probably aren't getting enough sleep, Corkins said. 'Even if you get a stimulant, it's not a substitute for sleep,' he said.
Research also suggests that children who consume more than 100 mg of caffeine during a school day are more likely than those who don't to struggle with self-control and behavioral issues.
For users of all ages, caffeine pouches, like nicotine pouches, may pose a threat to oral health, added Jackler, who in addition to studying tobacco marketing is an ear, nose and throat doctor. Routinely placing a foreign substance between the lips and gums may lead to gum recession and dental problems, so 'it's not necessarily an optimal way of taking in your caffeine, especially if it's something you're doing all day,' Jackler said.
Consumers should also be aware that caffeine pouches may not be tightly regulated, van Dam said. While the FDA has cracked down on the sale of 'pure and highly concentrated' caffeine products — like tubs of caffeine powder that contain thousands of servings that users must measure out themselves — caffeine pouches are regulated 'as either dietary supplements or conventional foods, depending on their composition and marketing,' an FDA spokesperson said. Supplements typically do not go through FDA review and approval before being sold to consumers.
Labeling is another concern, Jackler said: Some energy pouches on the market do not clearly state how much caffeine they contain.
Even with accurate labels, the potency of some caffeine pouches raises eyebrows. Two-hundred milligrams of caffeine is 'really the maximum amount that's being recommended in one sitting,' van Dam said, and some brands meet or exceed that amount in a single pouch.
The pouch industry isn't alone in that; energy drinks and coffee drinks can also pack in huge amounts of caffeine per serving, often also without clear labeling. But these products are both more familiar to consumers and easier to pace, in that people can stop sipping if they start to notice side effects, van Dam said. A caffeine pouch, by contrast, delivers a concentrated dose of caffeine fairly quickly, and 'once it's absorbed, it's absorbed,' he said.
Research also suggests that consuming nicotine and caffeine at the same time can compound their negative effects on the heart — a concern, given that some users alternate between nicotine and caffeine pouches.
Given these dangers, Jackler fears what could happen if caffeine pouches go the way of nicotine pouches, 'where kids put in four pouches in the upper lip and three pouches in the bottom lip,' he said. 'Young people, particularly, think that if a little bit helps, they're going to take even more.
This article was originally published on NBCNews.com
Solve the daily Crossword

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Health Line
36 minutes ago
- Health Line
Cold Sores
Cold sores are fluid-filled blisters that typically form on or near your lips. They usually clear up on their own within 10 days. Antiviral creams and medications can speed healing and relieve symptoms. A cold sore, sometimes referred to as a fever blister, typically starts with a tingling, itchy, or stinging feeling on or near your lips and mouth. Over the next 48 hours, one or more fluid-filled blisters will appear. Cold sores are contagious from the moment you first feel tingling to when they have completely healed. During this time, they can easily spread to other parts of your body and to other people through contact. To help keep cold sores from spreading: wash your hands with warm water and soap after touching your cold sore don't kiss anyone when you have a cold sore (especially babies) don't engage in oral sex until your cold sore is completely healed, as you can give your partner genital herpes Keep reading to learn more about cold sores, including their symptoms, appearance, causes, treatment, and prevention. What's the difference between a cold sore and a canker sore? Cold sores and canker sores both cause pain and discomfort, but that's where their similarities end. Canker sores are ulcers that form on the inside of the mouth, tongue, throat, and cheeks. They're usually flat lesions. They're not contagious and are not caused by the herpes simplex virus. Cold sores usually occur on the lips and outside the mouth. They're highly contagious. Cold sores are raised and have a 'bubbly' appearance.
Yahoo
an hour ago
- Yahoo
New Study Reveals the PERFECT Room Temperature for Sleeping
There's plenty of debate over what exactly the ideal room temperature is while sleeping. Some like it downright balmy while others prefer a chill to the air. Well, we can finally put a rest to the discourse because a new study from the National Sleep Foundation has revealed the optimal room temperature for snoozing. Be prepared to grab your favorite down comforter because the ideal temperature is around 65°F (18.3°C). News of the study was shared by the Instagram account @explain, but the full report can be found on the National Sleep Foundation website. The report, which was published earlier this month, goes into further detail on why resting in a room that's too stuffy can be detrimental to your sleep. "Warmer temperatures can cause discomfort and restlessness, and anyone who has slept in a stuffy bedroom can attest that it is hard to nod off when they are sweaty and dehydrated. A bedroom that is too warm can interfere with the body's thermoregulation abilities and cause fatigue. Often, a person who is fatigued will feel physically and mentally tired, but unable to fall asleep," the report revealed. While some people are thrilled at the confirmation that a cooler temperature is most ideal when it comes to sleeping, others aren't quite sure they can afford that cool comfort. "Tell that to my electric company.. if i set it at 65 in the summer I'd lose my house 😂," read one of the most liked comments under @explain's Instagram post. "Research also shows that you will need a second job to pay the electric bill," someone else chimed in. Will you be adjusting your thermostat tonight? You Might Also Like 15 Home Bar Gifts Every Cocktail Enthusiast Will Appreciate 32 Low Light Indoor Plants That Can Survive in the Darkest Corners of Your Home These Are the 50 Best Paint Colors for Your Living Room
Yahoo
an hour ago
- Yahoo
A Once-in-a-Lifetime Opportunity: This Blue Chip Healthcare Stock Down 50% Could Double Your Money
Key Points Novo Nordisk's recent financial results and clinical progress haven't impressed Wall Street. However, the company can right the ship through innovation in its core specialty and elsewhere. The stock looks attractively valued at current levels and could beat the market over the next six years. 10 stocks we like better than Novo Nordisk › Investors looking to strike while the iron is hot can buy beaten-down stocks that appear to have excellent chances of bouncing back. And that describes shares of Novo Nordisk (NYSE: NVO) very well. The pharmaceutical leader is down by 52% over the trailing-12-month period as of July 17, but initiating a position now could double investors' money in six years or so. Here's why this stock is a screaming buy at its current levels. Novo Nordisk's recent challenges Novo Nordisk focuses on developing diabetes treatments, an area where it has been a leader for many decades. As of February, it held a 33.3% market share for diabetes drugs. This sort of long-term dominance doesn't happen by accident. The company has consistently attracted top talent in the pharmaceutical industry, which, combined with its extensive experience in diabetes, has enabled it to break new ground repeatedly. Why, then, have the company's shares dropped by 52% over the past year? Because Novo Nordisk failed to impress the market with its financial results and clinical progress. The developments that led to the drugmaker's share plunge would have been excellent for almost any other pharmaceutical company, but investors held it to a higher standard given its rich valuation metrics. For instance, the company reported phase 3 results for CagriSema, an investigational weight management medicine, that proved it's more effective than its famous semaglutide (Wegovy), reducing patients' weight by an average of 22.7% in 68 weeks. However, management was looking for a 25% figure in the study. Very few anti-obesity therapies in development have achieved results comparable to CagriSema, but that was not enough to please investors. The good news: Novo Nordisk's pipeline in diabetes and the fast-growing area of weight management remains robust. The company has several promising candidates in development, including Amycretin, for which it recently initiated late-stage studies. And management has significantly expanded its pipeline through acquisitions. Even with mounting competition, the company should continue to be one of the leaders in its core areas of focus. It's been developing medicines in other fields as well, including various rare diseases (such as the blood disorders beta thalassemia and sickle cell disease), neurological disorders (including Alzheimer's and Parkinson's), and others. Making progress in diabetes and obesity while diversifying its lineup should work wonders for Novo Nordisk down the line. The price is right Net sales in the first quarter grew by 19% year over year to 78.1 billion Danish krone ($12.1 billion). The company's net profit was up 14% year over year to $4.5 billion. These would be excellent results for most similarly sized drugmakers, yet Wall Street remains unimpressed. In my view, that has created a wonderful opportunity to buy shares on the dip. The company's forward price-to-earnings ratio (P/E) has declined significantly over the past year and now stands at 16.9, barely above the healthcare industry's 16.2 and lower than the S&P 500's 22.3. But given Novo Nordisk's still excellent position in its core markets of diabetes and obesity treatments -- the latter of which should grow rapidly in the coming years -- and the company's better-than-average revenue and earnings growth, its stock is arguably worth a steeper premium. In fact, the forward P/E is about as low as it has been in over two years. At current levels, shares look like a steal. Here is how things could evolve for the company in the next six years. First, it could make significant clinical and regulatory progress and launch at least one -- if not several -- blockbuster weight loss or diabetes medications. Second, the company should continue recording strong results, with revenue and earnings moving in the right direction. Lastly, it looks likely to continue increasing its dividend, which it has done significantly over the past half-decade. The stock needs a compound annual growth rate of 12.2% to double in the next six years. Novo Nordisk can pull it off, especially for those who opt to reinvest the dividend. Should you buy stock in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Prosper Junior Bakiny has positions in Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. A Once-in-a-Lifetime Opportunity: This Blue Chip Healthcare Stock Down 50% Could Double Your Money was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data